AMSBIO has published an informative online article that reviews the importance of culture techniques for induced pluripotent stem cells (iPSCs), which provide an invaluable resource for drug discovery and therapeutic applications.
When using iPSCs for drug discovery and therapeutic applications, it is vital to generate a homogenous culture. The absence of uniformity in iPSC culture can severely compromise the quality and quantity of data generated.
The article discusses in detail how factors including maintaining genetic stability, optimizing culture conditions, and managing single…
Agreement builds on and complements Daiichi Sankyo and MSD’s shared commitment to develop novel medicines for patients with cancer
Daiichi Sankyo and MSD to co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where MSD retains exclusive rights
TOKYO & RAHWAY, N.J., August 6, 2024 – Daiichi Sankyo (TSE: 4568) and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) (NYSE: MRK) have expanded their existing global co-development and co-commercialization agreement for three investigational DXd…
Sandwich, Kent, UK / 6th August 2024 / Asymchem Laboratories (Tianjin) Co., Ltd. has officially inaugurated its new European development and pilot manufacturing site at Discovery Park in Sandwich, Kent, U.K., marked with a ribbon cutting on Friday 2 August by Dr. Hao Hong, Chairman, Founder, and CEO of Asymchem.
The former Pfizer small molecule facilities now employ 70 team members on-site in both the R&D labs and the API pilot plant, many of whom are legacy Pfizer employees. Additional hires are planned through to the end of the year as the pilot plant ramps up operations.
Building on a…
KISS is conducting a 2-minute survey to gather insights on the integration and usage of AI in business and marketing operations across different sectors including, Science, Technology, Education, Agriculture and Professional Services.
We are looking to help identify industry trends, support needs, and guide innovation and anonymised results will be shared with all participants.
Fill out the survey here.
Questions we are asking include:
What kind of training would be most beneficial for your organisation regarding AI and AI tools?
What are your primary concerns or worries regarding the use of…
Continuous 2 is an active project aiming to address the growing demand for cost-effective biologics treatments. With the global biopharmaceutical market estimated to grow to 3.9bn by 2024, the industry must act quickly to make these life-changing drugs more accessible to patients, and respond to the demand for flexible manufacturing technology that delivers real-time release of biotherapeutics.
UK Continuous 2 is building on the achievements of two previous projects:
UK Integrated Continuous Bioprocessing project 2020: this project established an integrated continuous downstream manufacturing…
The July edition of our People Pathways newsletter is now available to read here. You can read about:✴ New and upcoming One Nucleus courses✴ Registration open for the next BLSA SIG webinar✴ Reflections and takeaways from our Neurodiversity webinar✴ New mentoring opportunitiesand more...
French biophysics pioneer Depixus has launched its inaugural Research Program, offering free access to the company’s unique single molecule interactomics technology.
Depixus’ scalable magnetic force spectroscopy (MFS) platform is the first technology that allows researchers to simultaneously explore dynamic interactions between thousands of individual molecules in near real-time.
The platform is able to analyze interactions between various combinations of RNA, DNA, proteins, and small molecules, providing unprecedented insights into mechanisms of action, binding kinetics and more. It is…
One Nucleus and Life Science Nation unite for the Genesis 2024 and Redefining Early Stage Investments (RESI) Conferences to Amplify Impact on Life Science Innovation.
Boston MA and London UK, 31 July 2024 - One Nucleus and Life Science Nation (LSN) are pleased to announce the co-location of their renowned Genesis 2024 and Redefining Early Stage Investments (RESI) conferences, scheduled to take place on 4 December 2024, in London. The Genesis Conference programme will be at 1 Wimpole Street, and RESI will be at 11 Cavendish Square, allowing attendees to participate in either or both…
Metrion Biosciences' webinar ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ enabled attendees to learn how an hiPSC-CM model can help provide clear decision-making data for their project team, avoiding costly issues related to QTc and QRS cardiac liabilities in the clinic.
Presentations were received from:
Derek Leishman (VP Translational and Quantitative Toxicology at Eli Lilly and Company) presented the opportunities a sponsor now has available to increase the efficiency and effectiveness of QTc assessment by leveraging the ICH S7B core assays. He also discussed times when the…
Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.
Q2 2024 Take-Up Statistics
• Golden Triangle leasing activity totalled 39,700 sq ft in Q2 2024.
• This lull is typical for the second quarter, with 2024 likely to be the fourth year out of the past six where Q2 has reported the lowest quarterly volume of the year.
• Under-offer space totalled 131,500…